- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Soft Tissue Sarcoma/Rhabdomyosarcoma - July 2002
National Cancer Institute®
Last Modified: July 1, 2002
- Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for
- Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR.
- Fine-needle aspiration cytology of phyllodes tumors.
- Diagnosis of soft tissue tumors by fine-needle aspiration with combined cytopathology and ancillary techniques.
- [A clinicopathological study of clear cell sarcoma of the kidney]
- [Detection of SYT-SSX fusion gene in paraffin-embedded tissues and its clinicopathologic significance for synovial sarcoma]
- [Detection and analysis of SYT-SSX fusion gene in synovial sarcoma]
- [Giant cell fibroblastoma: a clinicopathologic analysis of seven cases]
- Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.
- Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth
- Pathological findings of gynecologic organs obtained at female radical cystectomy.
- Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
- Menstrual and reproductive factors and risk of soft tissue sarcomas.
- Can phyllodes tumours of the breast be distinguished from fibroadenomas using fine needle aspiration cytology?
- Penile cancer--surgical treatment of the primary tumor.
- Imatinib mesylate--a new oral targeted therapy.
- Current trials and new aspects in soft tissue sarcoma of adults.
- Molecular cytogenetic analysis consistently identifies translocations involving chromosomes 1, 2 and 15 in five embryonal rhabdomyosarcoma
- Infiltration of sarcomas into the hip joint: comparison of CT, MRI and histologic findings in 67 cases.
- Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro.
- The Lower Rhine Society for natural history and medicine in Bonn.
- [ANOCEF MEETING December 8, 2001. Summary of the meeting]
- Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma.
- Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.
- Retroperitoneal sarcoma: time for a national trial?
- Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.
- Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb
- Cardiac myxoma and myxosarcoma: clinical experience and immunohistochemistry.
- [Sarcoma of the uterus. Contemporary treatment and diagnostic protocol]
- [Soft tissue sarcoma in childhood: local treatment in patients under 3 years of age. Analysis of the RMS-88 multicenter study]
- Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of
- Adaptor protein-2 exhibits alpha 1 beta 1 or alpha 6 beta 1 integrin-dependent redistribution in rhabdomyosarcoma cells.
- Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis.
- Imaging of fatty tumors: distinction of lipoma and well-differentiated liposarcoma.
- Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.
- Detection of serum antibodies to three different recombinant antigens of human herpesvirus 8 by immunoblotting: seroprevalence studies in Taiwan.
- Uterine/female genital sarcomas.
- Radiation-induced sarcoma.
- Retroperitoneal sarcomas.
- Diagnosis of gastrointestinal stromal tumors: A consensus approach.
- Clinical management of gastrointestinal stromal tumors: before and after STI-571.
- Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.
- Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.
- Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
- Tamoxifen may increase risk of uterine sarcoma.
- Resection of the sciatic, peroneal, or tibial nerves: assessment of functional status.
- Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity.
- Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterisation of the lesion.
- Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
- Surgery for urogenital rhabdomyosarcoma.
- Phase II trial of gemcitabine in advanced sarcomas.
- Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma.
- Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative
- Reduced risk of synovial sarcoma in females: X-chromosome inactivation?
- [Subfascial lipomatous tumors: management in a series of 37 consecutive cases]
- PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas.
- Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol.
- Microsatellite instability in three cases of embryonal rhabdomyosarcoma of the orbit.
- Solitary fibrous tumors of the pleura.
Table of Contents
1
UI - 12021352
AU - Zhou FC; Zhang YJ; Deng JH; Wang XP; Pan HY; Hettler E; Gao SJ
TI -
Efficient infection by a recombinant Kaposi's sarcoma-associated
herpesvirus cloned in a bacterial artificial chromosome: application for
genetic analysis.
SO - J Virol 2002 Jun;76(12):6185-96
AD - Department of Pediatrics, The University of Texas Health Science Center
at San Antonio, 78229, USA.
Kaposi's sarcoma-associated herpesvirus (KSHV) is etiologically
associated with Kaposi's sarcoma and several other malignancies. The
lack of an efficient infection system has impeded the understanding of
KSHV-related pathogenesis. A genetic approach was used to isolate
infectious KSHV. Recombinant bacteria artificial chromosome (BAC) KSHV
containing hygromycin resistance and green fluorescent protein (GFP)
markers was generated by homologous recombination in KSHV-infected
BCBL-1 cells. Recombinant KSHV genomes from cell clones that were
resistant to hygromycin, expressed GFP, and produced infectious virions
after induction with tetradecanoyl phorbol acetate (TPA) were rescued in
Escherichia coli and reconstituted in 293 cells. Several 293 cell lines
resulting from infection with recombinant virions induced from a
full-length recombinant KSHV genome, named BAC36, were obtained. BAC36
virions established stable latent infection in 293 cells, harboring 1 to
2 copies of viral genome per cell and expressing viral latent proteins,
with approximately 0.5% of cells undergoing spontaneous lytic
replication, which is reminiscent of KSHV infection in Kaposi's sarcoma
tumors. TPA treatment induced BAC36-infected 293 cell lines into
productive lytic replication, expressing lytic proteins and producing
virions that efficiently infected normal 293 cells with a approximately
50% primary infection rate. BAC36 virions were also infectious to HeLa
and E6E7-immortalized human endothelial cells. Since BAC36 can be
efficiently shuttled between bacteria and mammalian cells, it is useful
for KSHV genetic analysis. The feasibility of the system was illustrated
through the generation of a KSHV mutant with the vIRF gene deleted. This
cellular model is useful for the investigation of KSHV infection and
pathogenesis.
2
UI - 12021355
AU - Fakhari FD; Dittmer DP
TI -
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus
by whole-genome real-time quantitative PCR.
SO - J Virol 2002 Jun;76(12):6213-23
AD - Department of Microbiology and Immunology, The University of Oklahoma
Health Science Center, Oklahoma City, Oklahoma 73104, USA.
The division into a latent or lytic life cycle is fundamental to all
herpesviridae. In the case of Kaposi's sarcoma-associated herpesvirus
(KSHV) (human herpesvirus 8), latent genes have been implicated in cell
autonomous transformation, while certain lytic genes procure a tumor
friendly milieu through paracrine mechanism. To query KSHV
transcription, we devised and validated a high-throughput,
high-specificity, high-sensitivity, real-time quantitative reverse
transcription-PCR array. This novel methodology is applicable to many
human pathogens. Its first use demonstrated that the mRNA levels for
KSHV LANA, v-cyclin, and v-FLIP do not increase at any time after viral
reactivation. The mRNA for LANA-2/vIRF-3 is similarly resistant to viral
reactivation. In contrast, every other latent or lytic message was
induced. Hence, LANA, v-FLIP, v-cyclin, and LANA-2 constitute a group of
uniquely regulated transcripts in the KSHV genome.
3
UI - 11933267
AU - Jayaram G; Sthaneshwar P
TI -
Fine-needle aspiration cytology of phyllodes tumors.
SO - Diagn Cytopathol 2002 Apr;26(4):222-7
AD - Department of Pathology, Faculty of Medicine, University of Malaya,
Kuala Lumpur. gita@ummc.edu.my
Breast lesions with a significant spindle cell or mesenchymal component
are not commonly encountered in fine-needle aspiration (FNA) cytologic
material and include a heterologous variety of benign and malignant
conditions, with phyllodes tumors (PTs) being the foremost differential
diagnostic consideration. This study comprises 28 tumors diagnosed
histologically as PT in which FNAC material was available for review.
Histological sections and cytological smears from these cases were
retrieved and subjected to detailed morphological review. Cytological
parameters assessed included ratio of stroma to epithelium, pattern
characteristics and cytological characteristics of the stromal, and
epithelial components and the background cells. Large and hypercellular
stroma fragments, dissociated spindle and plump stromal cells, often
accompanied by large, folded sheets of epithelium were cytological
features that characterized PT. Smears from malignant PT showed
predominantly or solely mesenchymal components. FNAC was a highly
reliable procedure for the diagnosis of PT, giving an accuracy rate of
92.8%. Copyright 2002 Wiley-Liss, Inc.
4
UI - 11933269
AU - Sapi Z; Antal I; Papai Z; Szendroi M; Mayer A; Jakab K; Pajor L; Bodo M
TI -
Diagnosis of soft tissue tumors by fine-needle aspiration with combined
cytopathology and ancillary techniques.
SO - Diagn Cytopathol 2002 Apr;26(4):232-42
AD - Department of Oncopathology, Semmelweis University of Health Sciences,
Budapest, Hungary. zsapi@freemail.hu
The diagnosis of mesenchymal neoplasm by fine-needle aspiration biopsy
(FNAB) has presented a diagnostic challenge. Most reports claim an
accuracy approaching 95%, but while they distinguish benign and
malignant lesions, the most problematic group, the intermediary
malignant group, is omitted. The purpose of this study was to determine
whether rapid cytologic diagnosis of soft-tissue tumors could guide
surgeons in therapeutic decisions without the need for a tissue biopsy.
Ninety-four FNA cytologic specimens were examined by the National Soft
Tissue Consortium of Hungary and compared with the corresponding
histology. Ordinary lipomas were excluded. Morphologic evaluation was
supplemented by ancillary techniques such as fluorescence in situ
hybridization (FISH), DNA cytometry, and immunocytochemistry. From a
practical clinicopathological point of view, the cases were grouped in
the following categories: 1) tumors with definitive diagnosis: a)
high-grade malignant neoplasms (high-grade sarcomas, metastatic
carcinomas, lymphoma), b) tumors with precise histogenetic origin by
cytogenetics, c) benign tumors; 2) tumors of questionable nature. In the
first group there were 74 tumors: 22 high-grade sarcomas, six metastatic
carcinomas, one malignant lymphoma, 16 malignant tumors in which the
precise histogenetic origin could be established by cytogenetic studies,
and 29 benign soft-tissue tumors other than lipomas. In the second group
there were 20 tumors comprising benign and malignant soft tissue tumors
of low grade, wherein the precise nature of the neoplasm could not be
established with confidence on cytologic study, even using ancillary
techniques. FNAB of soft-tissue tumors combined with ancillary
techniques should be considered a viable diagnostic technique for
therapeutic protocols. Although the second group is fairly large, we
have reliable, well-characterized categories which provide great freedom
for preoperative and surgical treatment, thus providing the best chance
for healing. Copyright 2002 Wiley-Liss, Inc.
5
UI - 11866983
AU - He L; Fu L; Wang L; Li P; Lang Z
TI -
[A clinicopathological study of clear cell sarcoma of the kidney]
SO - Zhonghua Bing Li Xue Za Zhi 2001 Dec;30(6):422-5
AD - Department of Pathology, Beijing Children's Hospital, Beijing 100045,
China.
OBJECTIVE: To study the clinicopathological, immunohistochemical
features and the histogenesis of clear cell sarcoma of the kidney
(CCSK). METHODS: CCSK specimens from 45 pediatric cases, including 31
male and 14 female with an age range from 3 months to 12 years (mean of
3.2 years), were retrieved. Routine pathological, immunohistochemical
and electron microscopic methods were utilized to analyze the CCSK
specimens. RESULTS: 35 of the 45 cases were followed from 6 to 192
months. 15 patients presented with bone metastases, 6 had lung or liver
metastases, 8 recurred and 20 died. Age and clinical stage at diagnosis
correlated with the rate of survival. Histologically, the classic
pattern of CCSK consisted of cells with pale cytoplasm, fine nuclear
chromatin and indistinct nucleoli separated by an arborizing
fibrovascular stroma. Other patterns were identified, including myxoid,
spindle, palisading, epithelioid, sclerosing, cellular, cystic, and
angiectatic. All tumors contained multiple patterns.
Immunohistochemically, all cases were positive for vimentin, but
negative for EMA, CK, desmin, actin, S-100, NSE, CD99, CD34 and LCA.
Electron microscopy of 9 cases showed features of primitive cell
conjunction and few organelles. CONCLUSION: CCSK is a common renal
neoplasm of childhood. CCSK may arise from renal mesenchymal cells and
has the propensity to metastasize to the bone with poor clinical
outcome.
6
UI - 11866984
AU - Wei Y; Sun M; Zhu H; Xu Z; Wang J; Zhu X
TI -
[Detection of SYT-SSX fusion gene in paraffin-embedded tissues and its
clinicopathologic significance for synovial sarcoma]
SO - Zhonghua Bing Li Xue Za Zhi 2001 Dec;30(6):426-30
AD - Department of Pathology, Cancer Hospital, Fudan University, Shanghai
200032, China.
OBJECTIVE: To investigate the feasibility of detecting SYT-SSX fusion
gene in paraffin-embedded tissues and its diagnostic significance for
synovial sarcoma (SS). METHODS: Formalin-fixed, paraffin-embedded
samples of 38 cases of SS and 40 cases of control tumors (including
spindle cell sarcoma and metastatic adenocarcinoma) were retrived from
archival materials. SYT-SSX fusion transcripts were detected in all
samples by RT-PCR. House-keeping gene Porphobilinogen Deaminase (PBGD)
was used to detect the quality of mRNA. RESULTS: PBGD mRNA was detected
in 64 of the 78 tumor cases (82.1%). SYT-SSX fusion transcripts was
detected in 33 of the 38 synovial sarcoma specimens. No SYT-SSX mRNA
expression was found in control tumors. SYT-SSX mRNA expression rate
reached 89.2% (33/37) in synovial sarcomas after exclusion of 1 case
which was negative for both SYT-SSX and PBGD. In 33 SYT-SSX positive
synovial sarcomas, 22 had SYT-SSX1 and 6 had SYT-SSX2 fusion
transcripts. In 5 cases, the fusion type could not be distinguished.
There was an association between SYT-SSX fusion type and histologic
subtype. All 10 biphasic synovial sarcoma cases had the SYT-SSX1 fusion,
whereas 12 of 18 monophasic synovial sarcoma had the SYT-SSX1 and 6 had
the SYT-SSX2 fusion gene (P < 0.05). CONCLUSIONS: (1) Detection of
SYT-SSX fusion gene in paraffin-embedded tissues was found to be a
sensitive and specific method for the diagnosis and differential
diagnosis of synovial sarcoma. (2) There was an association between
SYT-SSX fusion type and histologic subtype.SYT-SSX2 fusion transcript
could only be found in monophasic synovial sarcomas.
7
UI - 11866985
AU - Xu Z; Yang T; Wu B; Zhong H; Yang Z; Zhou B; Zhang C; Zheng J
TI -
[Detection and analysis of SYT-SSX fusion gene in synovial sarcoma]
SO - Zhonghua Bing Li Xue Za Zhi 2001 Dec;30(6):431-3
AD - Department of Pathology, Health Science Center, Peking University,
Beijing 100083, China.
OBJECTIVE: To demonstrate that a characteristic SYT-SSX fusion gene
resulting from chromosomal translocation t (X; 18) (p11; q11) was
detectable in archival paraffin-embedded synovial sarcoma tissues.
METHODS: SYT-SSX fusion transcripts in 20 synovial sarcomas (histologic
subtypes, 15 monophasic and 5 biphasic) were detected and analyzed by
the reverse-transcriptase polymerase chain reaction and compared with
the results from relevant pathological data. RESULTS: A specific SYT-SSX
RT-PCR product was found in 19 of 20 (95%) synovial sarcomas tested and
of the 13 tumors containing SYT-SSX2, 10 were monophasic. CONCLUSION:
SYT-SSX fusion transcripts are considered as a defining diagnostic
marker of synovial sarcomas and the subtypes of SYT-SSX fusion
transcripts (SYT-SSX1 and SYT-SSX2) may yield prognostic information.
8
UI - 11955334
AU - Wang J; Zhu X; Zhang R
TI -
[Giant cell fibroblastoma: a clinicopathologic analysis of seven cases]
SO - Zhonghua Bing Li Xue Za Zhi 2002 Feb;31(1):38-41
AD - Department of Pathology, Cancer Hospital, Fudan University, Shanghai
200032, China.
OBJECTIVE: To study the clinical, pathological and immunohistochemical
features of giant cell fibroblastoma (GCF), with emphasis on its
differential diagnosis and histogenesis. METHODS: Seven cases of GCF
were investigated by light microscopy and immunohistochemistry. RESULTS:
Six cases occurred in children, and one occurred in a 35 year-old adult
(mean 9.4 years). Five were male and two were female. Clinically, all
cases appeared as slowly growing painless nodules located in the dermis
or subcutis of the trunk and extremities. Microscopically, the poorly
circumscribed tumor was composed of a proliferation of slightly to
moderately atypical spindle cells which were arranged in parallel or
wavy fascicles, and embedded in a fibromyxoid to collagenous background.
The pathognomonic feature consisted of irregular distributed cleft-like
or sinusoid-like pseudovascular spaces lined with a discontinuous layer
of pleomorphic spindle cells and multinucleate giant cells. There was
transition in shape between these two cells. Immunohistochemially, both
cells expressed vimentin and CD34. Follow-up information in five cases
showed local recurrences in two cases. CONCLUSIONS: (1) GCF is a
distinctive fibroblastic tumor of intermediate malignancy that occurs
predominantly in children. Recognizing its clinical and pathological
characteristics is important to avoid misdiagnosis with other lesions
with similar features. (2) GCF shared clinical, immunohistochemical and
cytogenetic features with its adult counterpart-dermatofibrosarcoma
protuberans (DFSP). The additional coexistence of GCF and DFSP areas in
some primary cases and the reciprocal transformation in recurrent tumors
all suggest that they are two closely related entities, possibly
representing two members of the CD34 positive dendritic neoplasms.
9
UI - 12037676
AU - Yang K; Lui WO; Xie Y; Zhang A; Skytting B; Mandahl N; Larsson C;
TI -
Larsson O
Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.
SO - Oncogene 2002 Jun 13;21(26):4181-90
AD - Department of Oncology and Pathology, Karolinska Hospital CCK R8:04,
SE-171 76 Stockohlm, Sweden.
The chromosomal translocation t(X;18)(p11.2;q11.2) is tightly linked to
the tumorigenesis of synovial sarcoma. Through this translation the SYT
gene on chromosome 18 is fused with a testis/cancer antigen gene on the
X chromosome, generating either a SYT-SSX1, SYT-SSX2, or less often a
SYT-SSX4 fusion gene. It has been anticipated that the individual
synovial sarcoma carries only one of these variants, however, in this
study we demonstrated that SYT-SSX1 and SYT-SSX2 co-exist in a
significant proportion of the cases. From 121 SYT-SSX positive primary
tumors, co-expression of SYT-SSX1 and SYT-SSX2 was seen in 12 cases
(10%), which were characterized in further detail both at the RNA, DNA
and chromosomal level. In all 12 cases the SYT-SSX1 and SYT-SSX2 fusions
resulted in identical SYT-SSX fusion transcripts. However, at the
genomic level the translocations were different, and most likely
occurred between variable intronic sites in the target genes. By
interphase FISH analyses of 10 cases SYT-SSX2 translocations were found
to be the most abundant in all but one of the cases, in which SYT-SSX1
was predominating. The findings reveal a new heterogenous feature of
synovial sarcoma, accounting for approximately 10% of all cases, which
may shed light on the molecular genetic mechanisms behind translocations
in general, and on the etiology of synovial sarcoma in particular.
10
UI - 11786394
AU - Masood R; Cesarman E; Smith DL; Gill PS; Flore O
TI -
Human herpesvirus-8-transformed endothelial cells have functionally
activated vascular endothelial growth factor/vascular endothelial growth
factor receptor.
SO - Am J Pathol 2002 Jan;160(1):23-9
AD - Department of Pathology, Keck School of Medicine, University of Southern
California, Los Angeles, California, USA. masood@hsc.usc.edu
Kaposi's sarcoma is a vascular tumor commonly associated with human
immunodeficiency virus (HIV)-1 and human herpesvirus (HHV-8) also known
as Kaposi's sarcoma-associated herpesvirus. The principal features of
this tumor are abnormal proliferation of vascular structures lined with
spindle-shaped endothelial cells. HHV-8 may transform a subpopulation of
endothelial cells in vitro via viral and cellular gene expression. We
hypothesized that among the cellular genes, vascular endothelial growth
factors (VEGFs) and their cognate receptors may be involved in
viral-mediated transformation. We have shown that HHV-8-transformed
endothelial cells (EC-HHV-8) express higher levels of VEGF, VEGF-C,
VEGF-D, and PlGF in addition to VEGF receptors-1, -2, and -3.
Furthermore, antibodies to VEGF receptor-2 inhibited cell proliferation
and viability. Similarly, inhibition of VEGF gene expression with
antisense oligonucleotides inhibited EC-HHV-8 cell
proliferation/viability. The growth and viability of primary endothelial
cells and a fibroblast cell line however were unaffected by either the
VEGF receptor-2 antibody or the VEGF antisense oligodeoxynucleotides.
VEGF and VEGF receptors are thus induced in EC-HHV-8 and participate in
the transformation. Inhibitors of VEGF may thus modulate the disease
process during development and progression.
11
UI - 12050510
AU - Chang SS; Cole E; Smith JA Jr; Cookson MS
TI -
Pathological findings of gynecologic organs obtained at female radical
cystectomy.
SO - J Urol 2002 Jul;168(1):147-9
AD - Department of Urologic Surgery, Vanderbilt University Medical Center,
Nashville, Tennessee, USA.
PURPOSE: Historically anterior pelvic exenteration has been the
recommended treatment for invasive urothelial carcinoma in women
undergoing radical cystectomy. We evaluated the pathological features of
reproductive organs removed during exenteration to determine the
incidence of malignant pathology in these organs and the need for
removal. MATERIALS AND METHODS: We reviewed the records of all patients
Of these 382 patients, we identified 68 females who underwent radical
cystectomy for urothelial carcinoma. We reviewed preoperative, operative
and pathological findings, including bladder, lymph nodes, uterine and
adnexal pathology, in these female patients. RESULTS: Median patient age
was 64 years (range 35 to 86). Gynecologic organs were present in 40 of
the 68 surgical specimens (59%). The reasons for absent gynecologic
pathology were previous hysterectomy in 26 cases and the preservation of
organs during orthotopic urinary diversion creation in 2. Malignancy was
identified in 3 specimens, including invasive urothelial carcinoma in 2
(5%). In these 2 cases invasion was clearly identified intraoperatively.
Low grade stromal sarcoma of the uterus was present in 1 specimen (2%).
CONCLUSIONS: In the absence of clinical suspicion radical hysterectomy
at cystectomy rarely improves cancer control. Furthermore, secondary
malignancies are rare. The functional impact of preserving gynecologic
organs is a subject of ongoing study.
12
UI - 12065559
AU - Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C;
TI -
Sabbatini P; Tong W; Barakat R; Spriggs DR
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma:
results of a phase II trial.
SO - J Clin Oncol 2002 Jun 15;20(12):2824-31
AD - Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS),
particularly LMS that has progressed after doxorubicin treatment. We
sought to determine the response to gemcitabine plus docetaxel among
patients with LMS. PATIENTS AND METHODS: Patients with unresectable LMS
of uterine (n = 29) or other (n = 5) primary sites who did not respond
to zero to two prior chemotherapy regimens were enrolled onto a phase II
study of gemcitabine 900 mg/m(2) intravenously (i.v.) on days 1 and 8
plus docetaxel 100 mg/m(2) i.v. on day 8 with granulocyte
colony-stimulating factor given subcutaneously on days 9 to 15,
delivered every 21 days. Patients with prior pelvic radiation received
25% lower doses of both agents. Gemcitabine was delivered over 30 or 90
minutes in cycles 1 and 2 and by 90-minute infusion in all subsequent
cycles. Pharmacokinetic studies assessed in vivo differences in
gemcitabine concentrations with different rates of infusion. RESULTS:
Thirty-four patients (median age, 55 years; range, 32 to 74 years) have
enrolled. Fourteen had received prior pelvic radiation. Sixteen of 34
patients had progressed after doxorubicin-based therapy; 18 had no prior
chemotherapy. Among 34 patients, complete response was observed in three
patients and partial response in 15, for an overall response rate of 53%
(95% confidence interval, 35% to 70%). Seven patients had stable
disease. Fifty percent of patients previously treated with doxorubicin
responded. Hematologic toxicity was common (neutropenia: grade 3, 15%;
grade 4, 6%; thrombocytopenia: grade 3, 26%; grade 4, 3%), but
neutropenic fever (6%) and bleeding events (0%) were rare. The median
time to progression was 5.6 months (range, 4 to 10 months). CONCLUSION:
Gemcitabine plus docetaxel is tolerable and highly active in treated and
untreated patients with LMS.
13
UI - 10679647
AU - Fioretti F; Tavani A; Gallus S; Negri E; Franceschi S; La Vecchia C
TI -
Menstrual and reproductive factors and risk of soft tissue sarcomas.
SO - Cancer 2000 Feb 15;88(4):786-9
AD - Istituto di Ricerche Farmacologiche "Mario Negri," Milan, Italy.
BACKGROUND: Soft tissue sarcomas (STS) are a heterogeneous group of
neoplasms whose etiology remains largely undefined. A role for female
hormones in the development of STS has been suggested. To investigate
this possibility, the authors analyzed data from a hospital-based
case-control study conducted in Northern Italy between 1983 and 1998.
METHODS: Cases were 104 women aged < 79 years with incident STS who were
admitted to the cancer institutes and major teaching and general
hospitals. Controls were 505 women admitted to the same network of
hospitals for acute, nonneoplastic, nongynecologic, and
nonimmune-related conditions. RESULTS: The multivariate odds ratio (OR)
for women aged >/= 15 years compared with those aged < 12 years at
menarche was 1.94 (95% confidence intervals [95% CI], 0.80-4.74). No
association with STS risk was observed for menstrual cycle pattern, age
at menopause, parity, and abortions. Late age at first pregnancy and
birth were found to be related to an increased risk of STS, with an OR
of 3.16 (95% CI, 0. 96-10.44) and 2.79 (95%% CI, 0.79-9.90) for women
aged >/= 30 years at first pregnancy and birth compared with those aged
< 20 years. The trend in risk was significant for age at first
pregnancy. No relation with the risk of STS emerged for age at last
birth and time since first or last birth. CONCLUSIONS: The risk of STS
was found to be weakly related to late age at first pregnancy or birth,
but not to other menstrual and reproductive factors. Copyright 2000
American Cancer Society.
14
UI - 11827409
AU - Scolyer RA; McKenzie PR; Achmed D; Lee CS
TI -
Can phyllodes tumours of the breast be distinguished from fibroadenomas
using fine needle aspiration cytology?
SO - Pathology 2001 Nov;33(4):437-43
AD - Department of Anatomical Pathology and the Melanoma and Skin Cancer
Research Institute, Royal Prince Alfred Hospital, Camperdown, NSW,
Australia. rscolyer@csls.rpa.cs.nsw.gov.au
In an attempt to determine whether it is possible to distinguish
phyllodes tumours (PTs) of the breast from fibroadenomas (FAs) using
fine needle aspiration cytology (FNAC), we reviewed the cytological
slides of eight histopathologically confirmed PTs (six benign and two
malignant) and compared them with cytological features of 13
histopathologically confirmed FAs. Each author independently, "blindly"
assessed architectural and cytological features of the stromal (six
features) and epithelial (seven features) components and the cytological
background (three features) and gave a favoured diagnosis for each case.
Four of six benign PTs, one of two malignant PTs and 11 of 13 FAs were
correctly diagnosed cytopathologically by at least three of the authors.
The presence of hypercellular stromal fragments was the most useful
feature in distinguishing PTs from FAs, and the presence of cytological
atypia of the stromal cells was the most important feature in
distinguishing malignant from benign PTs. Sampling error was the most
common reason for cytological misdiagnosis of PTs. The two FAs
misdiagnosed as PTs were each of cellular type. The results of this
study suggest that it is possible to distinguish PTs from FAs using FNAC
in most cases. We recommend that if hypercellular stromal fragments are
identified in a FNAC specimen of a fibroepithelial lesion, the
cytopathologist should raise the possibility of a PT and the surgeon
treat the patient accordingly.
15
UI - 12087954
AU - Dechev IY; Banchev AB; Kadim MN; Zdravchev SA
TI -
Penile cancer--surgical treatment of the primary tumor.
SO - Folia Med (Plovdiv) 2001;43(4):46-50
AD - Medical University, Department of Urology, 15A Vassil Aprilov St., 4000
Plovdiv, Bulgaria.
OBJECTIVE: To present our experience in the surgical treatment of
primary tumor in penile cancer based on the accepted oncologic
principles and indications for the existing surgical methods of
treatment. MATERIAL AND METHODS: A retrospective analysis of 54 patients
with histologically proven malignant penile cancer treated surgically at
the Urology department of MHAT "St George", Plovdiv between 1975 and
performed. Penile amputations were significantly more than
penile-preserving operations. DISCUSSION: Differentiation and tumor
stage are paramount in the choice of surgical strategy for penile
cancer.
16
UI - 11870247
AU - Savage DG; Antman KH
TI -
Imatinib mesylate--a new oral targeted therapy.
SO - N Engl J Med 2002 Feb 28;346(9):683-93
AD - Herbert Irving Comprehensive Cancer Center, Columbia University College
of Physicians and Surgeons, New York, NY, USA.
17
UI - 12042982
AU - Issels RD; Schlemmer M
TI -
Current trials and new aspects in soft tissue sarcoma of adults.
SO - Cancer Chemother Pharmacol 2002 May;49 Suppl 1():S4-8
AD - Department of Internal Medicine III, Klinikum Grosshadern Medical
Center, Ludwig-Maximilians-University, Munich, Germany.
Issels@med3.med.uni-muenchen.de
PURPOSE: For high-risk soft tissue sarcoma (HR-STS) of adults new
treatment strategies are needed to improve outcome with regard to local
control and overall survival. Therefore, systemic chemotherapy has been
integrated either after (adjuvant) or before (neoadjuvant) optimal local
treatment by surgery and radiotherapy in HR-STS. METHODS AND RESULTS:
The Soft Tissue and Bone Sarcoma Group (STBSG) of the European
Organization for Research and Treatment of Cancer (EORTC) is conducting
an open randomized trial of adjuvant chemotherapy in high-grade primary
or recurrent STS at any site (EORTC 62931). In all cases primary surgery
should be curative in intent. All eligible patients are randomized after
completion of definitive surgery to receive either radiotherapy alone
with no further treatment (observation arm) or five cycles of
doxorubicin (70 mg/m(2)) plus ifosfamide (5 g/m(2)) using G-CSF to
support dose intensity followed by radiotherapy (chemotherapy arm). This
more aggressive chemotherapy regimen within an adjuvant setting might
retain sufficient antitumor activity to convert response rates into
survival benefit. At present more than 220 patients have been recruited
for this trial. To explain the rationale for the EORTC 62931 protocol,
reported results of other clinical adjuvant protocols including a
meta-analysis are given. In close collaboration with the European
Society of Hyperthermic Oncology (ESHO) the STBSG has also initiated a
randomized trial of neoadjuvant chemotherapy in primary or recurrent
HR-STS as an EORTC Intergroup study. According to the inclusion criteria
as defined (tumor size >or=5 cm + grade II or III + deep location +
extracompartmental extension) for the EORTC 62961/ESHO RHT-95 Intergroup
study, the majority of patients with HR-STS recruited for this pre- and
postoperative multimodality treatment protocol cannot be cured by
standard procedures. All eligible patients are randomized to receive
either four cycles of EIA (etoposide 250 mg/m(2) + ifosfamide 6 g/m(2) +
doxorubicin 50 mg/m(2)) within 12 weeks (chemotherapy arm) or the same
EIA regimen combined with regional hyperthermia (RHT + chemotherapy
arm). The patients then receive optimal local treatment using adequate
surgery immediately followed by radiotherapy. Thereafter an additional
four cycles of EIA chemotherapy are given with or without RHT according
to the initial randomization. At present more than 150 patients have
been recruited for this trial. The integration of RHT as a new potent
treatment modality if combined with EIA chemotherapy as first-line
treatment for well-defined risk groups is based upon encouraging
long-term results of phase II studies both in pretreated patients with
HR-STS and in those with locally advanced disease. CONCLUSIONS: In
summary, significant prognostic variables recognized for patients with
STS have been addressed in the design of two open phase III clinical
trials on adjuvant and neoadjuvant chemotherapy. The best chance for
offering such treatment strategies following evidence-based medicine
criteria to eligible patients with HR-STS depends upon early contact
with the coordinator of the individual protocol prior to any treatment.
18
UI - 12063389
AU - Roberts I; Gordon A; Wang R; Pritchard-Jones K; Shipley J; Coleman N
TI -
Molecular cytogenetic analysis consistently identifies translocations
involving chromosomes 1, 2 and 15 in five embryonal rhabdomyosarcoma
cell lines and a PAX-FOXO1A fusion gene negative alveolar
rhabdomyosarcoma cell line.
SO - Cytogenet Cell Genet 2001;95(3-4):134-42
AD - Hutchison/MRC Research Centre, Cambridge, UK. ir210@cam.ac.uk
Rhabdomyosarcoma in children is a "small round blue cell tumour" that
displays skeletal muscle differentiation. Two main histological variants
are recognised, alveolar (ARMS) and embryonal (ERMS) rhabdomyosarcoma.
Whereas consistent chromosome translocations characteristic of ARMS have
been reported, no such cytogenetic abnormality has yet been described in
ERMS. We have used multiple colour chromosome painting to obtain
composite karyotypes for five ERMS cell lines and one PAX-FOXO1A fusion
gene negative ARMS. The cell lines were assessed by spectral karyotyping
(SKY), tailored multi-fluorophore fluorescence in situ hybridisation
(M-FISH) using series of seven colour paint sets generated to examine
specific abnormalities, and comparative genomic hybridisation (CGH).
This approach enabled us to obtain karyotypes of the cell lines in
greater detail than previously possible. Several recurring cytogenetic
abnormalities were demonstrated, including translocations involving
chromosomes 1 and 15 and chromosomes 2 and 15, in 4/6 and 2/6 cell lines
respectively. All six cell lines demonstrated abnormalities of
chromosome 15. Translocations between chromosomes 1 and 15 have
previously been recorded in two primary cases of ERMS by conventional
cytogenetics. Analysis of the translocation breakpoints may suggest
mechanisms of ERMS tumourigenesis and may enable the development of
novel approaches to the clinical management of this tumour. Copyright
2002 S. Karger AG, Basel
19
UI - 12079023
AU - Ozaki T; Putzke M; Burger H; Gosheger G; Winkelmann W; Lindner N
TI -
Infiltration of sarcomas into the hip joint: comparison of CT, MRI and
histologic findings in 67 cases.
SO - Acta Orthop Scand 2002 Apr;73(2):220-6
AD - Department of Orthopaedics, Westfalische Wilhelms-University, Munster,
Germany. ozaki@uni-muenster.de
We analyzed the incidence, route, and characteristics of hip joint
infiltration in pelvic or proximal femoral sarcomas. 67 patients with a
sarcoma that originated around the hip joint (50 pelvic and 17 femoral)
were included in this study. Preoperative CT and MRI were matched with
the histological findings in tumor specimens. Tumor infiltration into
the hip joint was suspected on the basis of preoperative imaging in 29
patients due to articular cartilage disruption, diffuse signal changes
in the acetabulum or femoral neck, signs of a tumor in the joint, or
markedjoint effusion. Of these 29 patients, 15 showed tumor invasion on
histological examination. 12 of 31 chondrosarcomas, none of 12 Ewing's
sarcomas, and 3 of 24 osteosarcomas infiltrated into the hip joint (p =
0.008). 10 of 26 low-grade sarcomas and 5 of 41 high-grade sarcomas
infiltrated into the hip joint (p = 0.02). The joint infiltration rate
of the chondrosarcomas was related to their size. Of 10 tumors
originating in the acetabulum, 9 penetrated through or around the
osseous-ligamentous junction and one through the acetabular cartilage.
In 5 proximal femur lesions, all infiltrated the joint through the
femoral neck, 3 of them also through the ligamentum teres.
20
UI - 11731909
AU - Nagase H; Ikeda K; Sakai Y
TI -
Inhibitory effect of magnolol and honokiol from Magnolia obovata on
human fibrosarcoma HT-1080. Invasiveness in vitro.
SO - Planta Med 2001 Nov;67(8):705-8
AD - Department of Hygienics, Gifu Pharmaceutical University, Gifu, Japan.
nagase@gifu-pu.ac.jp
We investigated the inhibitory effect of Magnolia obovata Thunb. bark
ethanol extracts on human fibrosarcoma HT-1080 cells invasion in a
reconstituted basement membrane [Matrigel (MG)]. We found that the
effective components of the bark ethanol extracts were magnolol and
honokiol, two biphenyl compounds. The extracts, magnolol and honokiol,
did not affect HT-1080 cells adhesion to MG, but did inhibit HT-1080
cells migration at a high concentration (100 microM). HT-1080 cells
secrete matrix metalloproteinase (MMP)-9, which degrades the
extracellular matrix as a part of the invasive process. Magnolol and
honokiol inhibited the activity of MMP-9, which may have been
responsible, in part, for the inhibition of tumor cell invasiveness.
21
UI - 11907643
AU - Hobohm U
TI -
The Lower Rhine Society for natural history and medicine in Bonn.
SO - J Mol Med 2002 Feb;80(2):71; discussion 71-2
22
UI - 11984496
AU - Noel G; Mammar H; Ferrand R; Desblancs C; Nauraye C; Mazeron JJ
TI -
[ANOCEF MEETING December 8, 2001. Summary of the meeting]
SO - Rev Neurol (Paris) 2002 Apr;158(4):497-509
AD - Centre de protontherapie d'Orsay, Orsay, France.
23
UI - 12036902
AU - Fritz B; Schubert F; Wrobel G; Schwaenen C; Wessendorf S; Nessling M;
TI -
Korz C; Rieker RJ; Montgomery K; Kucherlapati R; Mechtersheimer G; Eils
R; Joos S; Lichter P
Microarray-based copy number and expression profiling in
dedifferentiated and pleomorphic liposarcoma.
SO - Cancer Res 2002 Jun 1;62(11):2993-8
AD - Deutsches Krebsforschungszentrum, Abteilung Molekulare Genetik (H0700),
Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
Sixteen dedifferentiated and pleomorphic liposarcomas were analyzed by
comparative genomic hybridization (CGH) to genomic microarrays
(matrix-CGH), cDNA-derived microarrays for expression profiling, and by
quantitative PCR. Matrix-CGH revealed copy number gains of numerous
oncogenes, i.e., CCND1, MDM2, GLI, CDK4, MYB, ESR1, and AIB1, several of
which correlate with a high level of transcripts from the respective
gene. In addition, a number of genes were found differentially expressed
in dedifferentiated and pleomorphic liposarcomas. Application of
dedicated clustering algorithms revealed that both tumor subtypes are
clearly separated by the genomic profiles but only with a lesser power
by the expression profiles. Using a support vector machine, a subset of
five clones was identified as "class discriminators." Thus, for the
distinction of these types of liposarcomas, genomic profiling appears to
be more advantageous than RNA expression analysis.
24
UI - 12103287
AU - O'Sullivan B; Davis AM; Turcotte R; Bell R; Catton C; Chabot P; Wunder
TI -
J; Kandel R; Goddard K; Sadura A; Pater J; Zee B
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of
the limbs: a randomised trial.
SO - Lancet 2002 Jun 29;359(9325):2235-41
AD - Department of Radiation Oncology, Princess Margaret Hospital, University
of Toronto, Ontario, Canada. brian.osullivan@rmp.uhn.on.ca
BACKGROUND: External-beam radiotherapy (delivered either preoperatively
or postoperatively) is frequently used in local management of sarcomas
in the soft tissue of limbs, but the two approaches differ substantially
in their potential toxic effects. We aimed to determine whether the
timing of external-beam radiotherapy affected the number of wound
healing complications in soft-tissue sarcoma in the limbs of adults.
METHODS: After stratification by tumour size (< or = 10 cm or >10 cm),
we randomly allocated 94 patients to preoperative radiotherapy (50 Gy in
25 fractions) and 96 to postoperative radiotherapy (66 Gy in 33
fractions). The primary endpoint was rate of wound complications within
120 days of surgery. Analyses were per protocol for primary outcomes and
by intention to treat for secondary outcomes. FINDINGS: Median follow-up
was 3.3 years (range 0.27-5.6). Four patients, all in the preoperative
group, did not undergo protocol surgery and were not evaluable for the
primary outcome. Of those patients who were eligible and evaluable,
wound complications were recorded in 31 (35%) of 88 in the preoperative
group and 16 (17%) of 94 in the postoperative group (difference 18% [95%
CI 5-30], p=0.01). Tumour size and anatomical site were also significant
risk factors in multivariate analysis. Overall survival was slightly
better in patients who had preoperative radiotherapy than in those who
had postoperative treatment (p=0.0481). INTERPRETATION: Because
preoperative radiotherapy is associated with a greater risk of wound
complications than postoperative radiotherapy, the choice of regimen for
patients with soft-tissue sarcoma should take into account the timing of
surgery and radiotherapy, and the size and anatomical site of the
tumour.
25
UI - 11986182
AU - Brennan MF
TI -
Retroperitoneal sarcoma: time for a national trial?
SO - Ann Surg Oncol 2002 May;9(4):324-5
26
UI - 11986186
AU - Jones JJ; Catton CN; O'Sullivan B; Couture J; Heisler RL; Kandel RA;
TI -
Swallow CJ
Initial results of a trial of preoperative external-beam radiation
therapy and postoperative brachytherapy for retroperitoneal sarcoma.
SO - Ann Surg Oncol 2002 May;9(4):346-54
AD - University of Toronto Sarcoma Group, Princess Margaret Hospital,
Toronto, Ontario, Canada.
BACKGROUND: Surgical resection alone does not cure the majority of
patients with retroperitoneal sarcoma (RPS). We evaluated the effects of
preoperative external-beam radiotherapy (XRT) and postoperative
brachytherapy (BT) combined with complete surgical resection. METHODS:
Fifty-five patients with primary or locally recurrent RPS judged to be
resectable were entered onto a trial of combined therapy and observed
prospectively. Forty-six patients underwent complete gross resection
with curative intent. Of these, 41 patients completed preoperative XRT
and 23 patients received BT. Outcome measures were treatment toxicity,
overall survival, and disease-free survival (DFS). RESULTS: Preoperative
XRT was very well tolerated and was associated with Radiation Therapy
Oncology Group acute toxicity scores of < or = 2 in all patients. Acute
postoperative and BT-related toxicity resulted in modified RTOG scores
of > or = 3 in 39.1% (18 of 46) of patients. Late toxicity was
associated with death in 4.3% (2 of 46) and with life-threatening
illness in 2.2% (1 of 46) of patients, all of whom had been treated with
BT to the upper abdomen. The 2-year overall survival and DFS for
resected RPS were 88% and 80%, respectively. Significantly better 2-year
DFS was achieved in patients with primary RPS and in those with
low-grade tumors (93% and 95%, respectively). CONCLUSIONS: The initial
results of combined therapy are promising. Although preoperative XRT was
very well tolerated, BT to the upper abdomen was associated with
substantial toxicity. Our current protocol includes selective
application of BT to the lower abdomen only.
27
UI - 11986187
AU - van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
TI -
Value of continuous leakage monitoring with radioactive
iodine-131-labeled human serum albumin during hyperthermic isolated limb
perfusion with tumor necrosis factor-alpha and melphalan.
SO - Ann Surg Oncol 2002 May;9(4):355-63
AD - Department of Surgical Oncology, Groningen University Hospital,
Groningen, The Netherlands.
BACKGROUND: The aim of this study was to analyze the value of continuous
leakage monitoring with radioactive iodine-131-labeled human serum
albumin (RISA) in patients treated with hyperthermic isolated limb
perfusion with tumor necrosis factor-alpha (TNF alpha) and melphalan.
METHODS: Forty-eight patients with melanoma (n = 14) or soft tissue
sarcoma (n = 34) of an extremity underwent 51 perfusions. Perfusion was
performed at the iliac level in 22 cases, at the popliteal level in 16
cases, at the femoral level in 7 cases, and at the axillary level in 6
cases. Leakage rates and perfusion circuit and systemic levels of TNF
alpha, interleukin-6, and C-reactive protein were determined, as were
systemic hematological and metabolic profiles and tumor response.
RESULTS: The mean isotopically measured leakage was 2.9%. Systemic
leakage was < or = 2% in 28 perfusions and >2% in 23 perfusions. The
correlation between the maximal monitored leakage and maximal systemic
TNF alpha levels was.7114. The area under the curve for TNF alpha in the
perfusion circuit, indicating the exposure of the perfused limb to TNF
alpha, was 18.7% lower in the >2% leakage group. No significant
differences in tumor response were found between groups. The area under
the curve for systemic TNF alpha, indicating the exposure of the patient
to TNF alpha, was 18.1 times higher in the >2% leakage group, resulting
in a significant decrease in leukocyte and platelet count,
hyperbilirubinemia, hypocholesterolemia, and proteinemia. No beneficial
effect of the systemically leaked TNF and melphalan was seen on the
occurrence of distant metastasis during follow-up. There was a
significant difference between perfusions performed at the iliac and
femoral levels compared with leakage values at the popliteal level.
CONCLUSIONS: A good correlation between RISA leakage measurement and TNF
alpha exposure during and after hyperthermic isolated limb perfusion
with TNF alpha and melphalan was demonstrated. RISA leakage measurement
serves as a good guide for the effectiveness of isolation during
perfusion. If leakage exceeds the 2% limit during perfusion, less
exposure of the tumor-bearing limb to TNF alpha, increased exposure of
the patient systemic circulation to TNF alpha, and more systemic side
effects can be expected.
28
UI - 12079962
AU - Liu S; Wang Z; Chen AQ; Zhou GH; Jiang ZB; Xiao MD
TI -
Cardiac myxoma and myxosarcoma: clinical experience and
immunohistochemistry.
SO - Asian Cardiovasc Thorac Ann 2002 Mar;10(1):8-11
AD - Department of Cardiovascular Surgery, Shanghai First People's Hospital,
Shanghai, People's Republic of China. drliusha@yahoo.com
females) with cardiac myxoma (115) or myxosarcoma (5) underwent surgical
excision or biopsy. There were 5 early postoperative deaths (mortality,
4.2%). Seventy-three survivors were followed up for 0.75 to 20.25 years
(mean, 9.42 years); they comprised 4 myxosarcoma patients who all had
recurrence or metastasis, and 69 myxoma patients who had no evidence of
recurrence or metastasis. Neither familial myxoma nor Carney complex was
found. The 5 cases of myxosarcoma and 18 randomly selected cases of
myxoma were evaluated for proliferative activity, metastatic potential,
and oncogene products by immunohistochemistry. The expression of p53 and
Bcl-2 was similar in both groups. Overexpression of proliferating cell
nuclear antigen and low expression of nm23 in myxosarcoma are consistent
with the high rate of recurrence and metastasis of this tumor. Surgical
resection of sporadic myxoma is a safe and effective treatment with
satisfactory early and long-term results. However, the prognosis of
myxosarcoma is still disappointing. Regular echocardiography and chest
radiography or computed tomography are necessary for early detection of
recurrence or metastasis of myxosarcoma.
29
UI - 11799758
AU - Ko
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
